Post-earnings recap
Reported
Wed, Nov 9, 2022
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Terns Pharmaceutical is still facing challenges, as reflected in the EPS miss. The stock dropped 8.1% following the announcement, likely due to investor concerns over the lack of revenue data and guidance. The defensive tone from management suggests they are cautious about the near-term outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.44 | N/A | +13.21% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about the competitive landscape and its impact on performance. They reiterated their commitment to navigating these challenges.
Management acknowledged ongoing challenges in the market.
They emphasized a focus on long-term strategies despite current setbacks.